Evidence map›Paper›PMID 38159861›Full record

ArticleThe Journal of biological chemistry2024

Crystal structure of bacterial ubiquitin ADP-ribosyltransferase CteC reveals a substrate-recruiting insertion.

Zhengrui Zhang, Hannah M Rondon-Cordero, Chittaranjan Das

Open access · goldAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Zhengrui ZhangDepartment of Chemistry, Purdue University, West Lafayette, Indiana, USA.
Hannah M Rondon-CorderoDepartment of Chemistry, Purdue University, West Lafayette, Indiana, USA.
Chittaranjan DasDepartment of Chemistry, Purdue University, West Lafayette, Indiana, USA. Electronic address: cdas@purdue.edu.
Purdue University West Lafayette · US

Funding

Mechanism of atypical ubiquitination and deubiquitination by bacterial effectorsR01GM126296 · NIGMS · PURDUE UNIVERSITY · PI Chittaranjan Das · 2018 to 2026
$3.6M
Drug Discovery in Infectious Disease TrainingT32AI148103 · NIAID · PURDUE UNIVERSITY · PI STAHELIN, ROBERT VIRGIL, YEO, YOON · 2020 to 2024
$949k
DeADP-ribosylation of host targets mediated by a bacterial effectorR21AI171709 · NIAID · PURDUE UNIVERSITY · PI DAS, CHITTARANJAN · 2023 to 2024
$426k
NIAID NIH HHS R21 AI171709NIAID NIH HHS T32 AI148103NIGMS NIH HHS R01 GM126296
6 · The paper itself

Abstract

ADP-ribosylation is a post-translational modification involved in regulation of diverse cellular pathways. Interestingly, many pathogens have been identified to utilize ADP-ribosylation as a way for host manipulation. A recent study found that CteC, an effector from the bacterial pathogen Chromobacterium violaceum, hinders host ubiquitin (Ub) signaling pathways via installing mono-ADP-ribosylation on threonine 66 of Ub. However, the molecular basis of substrate recognition by CteC is not well understood. In this article, we probed the substrate specificity of this effector at protein and residue levels. We also determined the crystal structure of CteC in complex with NAD

Indexed as

ADP Ribose TransferasesBacterial ProteinsModels, MolecularADP-RibosylationChromobacteriumCrystallography, X-RayNADProtein BindingProtein DomainsProtein Structure, TertiarySubstrate SpecificityUbiquitinADP Ribose TransferasesBacterial ProteinsNADUbiquitinADP-ribosylationbacterial toxinhost–pathogen interactionisothermal titration calorimetryprotein crystallizationubiquitin

Identifiers

PMID38159861
PMCPMC10810742
OpenAlexW4390323607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.